Consumer sleep trackers (Fitbit, Apple Watch, Oura, Whoop) misclassify sleep stages with F1 scores as low as 0.26, yet clinicians increasingly encounter patients self-diagnosing based on tracker data

A 2025 multicenter validation study comparing 11 consumer sleep trackers against polysomnography found macro F1 scores for sleep stage classification ranging from 0.26 to 0.69, meaning the best consumer device still misclassifies roughly one-third of sleep epochs and the worst misclassifies three-quarters -- yet these devices are worn by over 100 million users globally and are increasingly brought into clinical consultations as evidence of sleep disorders. Why it matters: patients who see their Oura ring or Apple Watch report low deep sleep or high wake-after-sleep-onset develop anxiety about their sleep quality (a phenomenon termed 'orthosomnia'), so they seek clinical evaluation for a disorder they may not have, consuming scarce sleep medicine appointments, so clinicians must spend consultation time explaining device limitations rather than addressing genuine pathology, so the patients who are reassured often distrust the clinician and seek second opinions or self-treat with supplements and OTC sleep aids, so the devices that could theoretically democratize sleep health monitoring instead generate noise that degrades the signal-to-noise ratio in an already overburdened specialty. The structural root cause is that consumer sleep tracker companies use proprietary black-box algorithms trained on limited polysomnography datasets (predominantly young, healthy, white participants), do not publish validation data for clinical populations, and can silently change their scoring algorithms through firmware updates without re-validation -- and no FDA clearance is required because the devices are marketed as wellness products rather than medical devices.